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Abstract 
Background: Malaria remains an important cause of morbidity and mortality in India. Though many comprehensive 
studies have been carried out in Africa and Southeast Asia to characterize and examine determinants of Plasmodium 
falciparum and Plasmodium vivax malaria pathogenesis, fewer have been conducted in India.
Methods: A prospective study of malaria‑positive individuals was conducted at Goa Medical College and Hospital 
(GMC) from 2012 to 2015 to identify demographic, diagnostic and clinical indicators associated with P. falciparum and 
P. vivax infection on univariate analysis.
Results: Between 2012 and 2015, 74,571 febrile individuals, 6287 (8.4%) of whom were malaria positive, presented to 
GMC. The total number of malaria cases at GMC increased more than two‑fold over four years, with both P. vivax and 
P. falciparum cases present year‑round. Some 1116 malaria‑positive individuals (mean age = 27, 91% male), 88.2% of 
whom were born outside of Goa and 51% of whom were construction workers, were enroled in the study. Of 1088 
confirmed malaria‑positive patients, 77.0% had P. vivax, 21.0% had P. falciparum and 2.0% had mixed malaria. Patients 
over 40 years of age and with P. falciparum infection were significantly (p < 0.001) more likely to be hospitalised 
than younger and P. vivax patients, respectively. While approximately equal percentages of hospitalised P. falciparum 
(76.6%) and P. vivax (78.9%) cases presented with at least one WHO severity indicator, a greater percentage of P. falcipa-
rum inpatients presented with at least two (43.9%, p < 0.05) and at least three (29.9%, p < 0.01) severity features. There 
were six deaths among the 182 hospitalised malaria positive patients, all of whom had P. falciparum.
Conclusion: During the four year study period at GMC, the number of malaria cases increased substantially and the 
greatest burden of severe disease was contributed by P. falciparum.
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Background
Globally, parasites of the Plasmodium genus infect more 
than 200 million people and cause an estimated 438,000 
deaths annually [1]. India is the second most populous 
country in the world with ongoing malaria transmission, 
with 91% of its more than 1.2 billion population living 
in areas of malaria risk [1]. The most recent estimates 
report up to 26 million malaria cases and 55,000 deaths 
due to malaria annually in India [1]. However, there is 
ongoing, vigorous debate about these figures, in part due 
to the vast scale of the country [2–5].
India is co-endemic for Plasmodium falciparum and 
Plasmodium vivax, posing challenges for malaria control 
and elimination planning because the two parasite spe-
cies may differ in mosquito vectors, spatial distributions 
and transmission dynamics and because of the relapsing 
nature of P. vivax infection with a dormant liver stage 
[6–8]. Overall, approximately 66% of malaria infections 
in India are caused by P. falciparum and 34% are caused 
by P. vivax [1]. However, the proportional distribution 
varies across India and a wide range of clinical presenta-
tions are seen from both predominant species of malaria 
[6]. In contrast to Africa, malaria transmission in India is 
more limited, both adolescents and adults are at risk of 
severe malaria, and a substantial proportion of cases are 
infected with P. vivax rather than the traditionally more 
virulent P. falciparum. Although many expansive and 
comprehensive studies have been carried out in Africa 
[9–14] and Southeast Asia [15–20] to examine patho-
genesis and mortality determinants in malaria-positive 
patients, a more limited number of such studies, gener-
ally smaller in scope, have been conducted within India 
[21–29].
India has one of the world’s largest and most extensive 
national surveillance systems to identify malaria inci-
dence [30, 31] and is a highly heterogeneous country with 
more than 2000 ethnic groups and 22 official languages 
spread across 29 states and seven union territories. All of 
these states have populations in the millions and a more 
than ten-fold variation in average per capita income [32], 
which leads to important geographic variations in disease 
epidemiology and substantial variability in the delivery of 
malaria diagnosis, care and treatment across the country 
[33]. It would be costly and operationally difficult to meas-
ure all of the diverse malaria settings in India through 
community-based surveys or reactive case-detection 
methods [34] and challenging to comprehensively address 
every environmental context through national-level strat-
egies, programmes and recommendations [35, 36].
In addition to India’s vast countrywide and state-level 
monitoring of malaria, rigorous hospital-based reports 
can provide epidemiological data relevant to local control 
and elimination initiatives as well as clinical data relevant 
to diagnosis, care and treatment efforts. Clinicians, as 
well as the wider public health system, may benefit from 
deep studies of specific patient pools in order to bet-
ter understand malaria transmission and pathogenesis 
in local communities. Such information may also assist 
in the prioritization of resources for patient care and 
treatment.
With the aim of conducting methodical studies in a 
low to mid-endemicity, peri-urban setting, the Malaria 
Evolution in South Asia (MESA) International Center 
of Excellence for Malaria Research (ICEMR) established 
a research site at Goa Medical College and Hospital 
(GMC) [37–39]. Previously an overseas province of Por-
tugal, Goa is a small, prosperous, southwestern state of 
India where both P. falciparum and P. vivax are endemic. 
GMC is the only government tertiary care centre in the 
state and operates under the auspices of the Government 
of Goa Public Health Department to provide health care 
to all, free-of-charge. The relatively advanced diagnos-
tic and clinical capabilities at GMC draw a large, diverse 
patient pool and allow for deep clinical analysis. As a 
research site, GMC offers a highly heterogeneous patient 
population, a constant flow of febrile and malaria-posi-
tive cases, and a wide spectrum of clinical presentations 
of malaria in a relatively affluent, burgeoning peri-urban 
area. The present study provides a detailed description of 
the demographic, diagnostic and clinical characteristics 




The present work was part of the US National Institutes 
of Health-sponsored Program Project [40, 41] entitled 
Malaria Evolution in South Asia International Center of 
Excellence for Malaria Research (MESA-ICEMR). The 
activities of this centre were approved by the Govern-
ment of India (GOI) Health Ministry Screening Com-
mittee (HMSC) and the Government of Goa Public 
Health Department. The human subjects protocol and 
consent forms for enrolment of Plasmodium-positive 
individuals presenting to Goa Medical College and 
Hospital (Bambolim, Goa, India) were approved by 
the institutional review boards (IRB) of the Division of 
Microbiology and Infectious Diseases (DMID) at the 
US National Institute of Allergy and Infectious Dis-
eases (NIAID), GMC, and the University of Washington 
(UW).
Study design and enrolment
All febrile individuals presenting to the outpatient, pae-
diatric, and casualty departments of GMC were tested by 
hospital staff for Plasmodium infection via finger-prick 
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or venous blood draw and examination by microscopy of 
Giemsa-stained thin blood smear and/or by rapid diag-
nostic test (RDT), FalciVax, Zephyr Biomedicals). The 
hospital generally only used one method of testing per 
individual, usually microscopy. In rare instances, both 
RDT and microscopy were used. If the RDT or micros-
copy was positive, the individual was counted as malaria 
positive. If the RDT and microscopy showed different 
species of parasite, the individual was counted as mixed 
infection positive. Hospital-determined malaria positiv-
ity and species of infection results are presented for all 
febrile patients presenting to GMC between January 2012 
and December 2015.
Individuals determined to be malaria positive by either 
microscopy or RDT by the hospital, who were between 
the ages of 12  months and 65  years and not pregnant, 
were referred to the MESA-ICEMR study team. Enrol-
ment generally occurred during normal working hours 
and when study staff were not completing enrolment of a 
previous patient.
Outpatients and individuals admitted to the Medi-
cine, Paediatric, and Intensive Cardiac Care Unit 
(ICCU) wards were approached for participation in the 
study. Severely ill individuals requiring use of a ventila-
tor and, therefore, admitted to the Intensive Care Unit 
(ICU) were not approached for inclusion in this study. 
Malaria-positive individuals were given oral and writ-
ten descriptions of the study and were asked to provide 
written informed consent or, in the case of children 
between 12  months and 18  years, consent of a parent 
or guardian or, in the case of children between the ages 
of eight and 18 years, assent in addition to the consent 
of a parent or guardian. Each study participant received 
a unique numerical code in order to streamline data 
collection.
Upon enrolment, study participants provided demo-
graphic information as well as history of malaria infec-
tion, symptoms and travel to study staff. Following 
venous blood draw into vacutainers (ACD, BD, India), 
study participants received care and treatment as 
directed by the attending physician at GMC.
Sample processing
Each venous blood sample was transferred to the on-site 
MESA-ICEMR research laboratory. Research staff imme-
diately prepared three thin and two thick blood smears. 
Plasmodium species and parasitaemia were determined 
by Giesma-stained thick smear reading by expert micros-
copists. Research staff then performed an additional RDT 
(FalciVax, Zephyr Biomedicals, India) and measured hae-
moglobin (Hb 201, HemoCue, USA) and haematocrit 
(Iris StatSpin, Beckman Coulter, USA).
In addition to the hospital determination used for ini-
tial recruitment, research study staff also made a sepa-
rate, independent determination of malaria positivity 
and species of infection based on diagnostic tests con-
ducted in the MESA-ICEMR laboratory. If both RDT 
and microscopy results were negative in the MESA-
ICEMR lab, the patient was classified as an unconfirmed 
case. If RDT or microscopy was positive, the patient was 
counted as a confirmed malaria positive case. If the RDT 
and microscopy showed different species of parasite, the 
sample was identified as mixed infection positive. Indi-
viduals enroled in the study who were determined to be 
malaria positive by the hospital, but who were classi-
fied as malaria negative by the research study staff were 
excluded from statistical analysis of demographic, diag-
nostic and clinical characteristics. Study-determined 
positivity and species of infection results are presented 
from April 2012 through December 2015.
Clinical characteristics and severity scores
Measured features among all enroled patients with con-
firmed malaria infection were: high parasitaemia (>4.0% 
for P. falciparum, >1.5% for P. vivax); hyperparasitaemia 
(>10% for P. falciparum, >2.0% for P. vivax); high fever 
(>38.1  °C); severe fever (>38.9  °C); anaemia (haemoglo-
bin (Hb) < 9 g/dL in those 12 years and older, Hb < 7 g/
dL in those 1–11 years); and severe anaemia (Hb < 7 g/
dL in those 12  years and older, Hb  <  5  g/dL in those 
1–11  years). Patients were admitted to GMC based on 
the clinical judgement of the attending physician and did 
not have to fulfil any WHO criteria for severe malaria 
classification.
Enroled P. falciparum- and P. vivax-positive patients 
who were hospitalised were assessed daily by trained 
GMC clinicians for severity of infection based on WHO 
criteria [42, 43]. Measured features among enroled, 
hospitalised patients associated with severe malaria 
infection were: cerebral malaria (Glasgow coma score 
<11 in adults or Blantyre coma score <3 in children 
and presence of asexual forms in blood); hypoglycae-
mia (blood glucose  <  40  mg/dL); metabolic acidosis 
(plasma bicarbonate < 15 mmol/L), renal failure (serum 
creatinine  >  3.0  ml/dL and/or blood urea nitrogen 
(BUN)  >  17  mmol/L); abnormal bleeding (observ-
able); respiratory distress (breathing rate  >  20 breaths/
min or partial oxygen (PaO2)  <  75); severe jaundice 
(total bilirubin  >  10  mg/dL); circulatory collapse/shock 
(systolic blood pressure (BP)  <  80  mmHg with cold 
extremities); pulmonary oedema (observable); severe 
anaemia (Hb  <  7  g/dL or haematocrit (HCT)  <  20% in 
those 12  years and older, Hb  <  5  g/dL or HCT  <  15% 
in those one to 11  years); and death. Occasionally, the 
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complete clinical laboratory investigation panel was not 
ordered [42, 43]. A severity score (SS) was calculated 
for all hospitalised patients based on the total number 
of WHO severe malaria criteria met at enrolment and 
throughout hospitalisation.
Meteorological data
Rainfall data for Goa were obtained from the India Mete-
orological Department (IMD) (Ministry of Earth Sci-
ences, Government of India). Data were collected at 
the IMD observatory in the capital city of Goa, Panaji, 
located roughly 5 km from GMC.
Data and sample management
Demographic and clinical study data were collected 
and managed using REDCap electronic data capture 
tools (Nashville, TN, USA). Diagnostic study data were 
recorded and stored using LabKey software (Seattle, WA, 
USA). All samples and associated aliquots were labelled 
and stored using a customized FreezerPro database 
(RURO Inc, Frederick, MD, USA).
Statistical analysis
Data were initially entered into a customized SQL data-
base (LabKey server) followed by independent verifica-
tion against the original case report forms. Statistical 
differences between percent parasitaemias between spe-
cies for all enroled patients, inpatients and outpatients 
were determined using an unequal variance t test using 
GraphPad Prism 6 software (La Jolla, CA, USA). All other 
analyses were conducted using R (Vienna, Austria).
For univariate analysis, the primary outcome was 
the species of malaria infection. Continuous variables 
were summarized with mean and standard deviation 
and binary variables were summarized with propor-
tions. Between group univariate comparisons of fea-
tures for P. falciparum and P. vivax were analysed with 
logistic regression. Demographic and diagnostic fea-
tures were reported for all confirmed P. falciparum and 
P. vivax-infected enroled patients. Clinical laboratory 
tests and classifications were only reported for confirmed 
P. falciparum and P. vivax-infected inpatients and were 
included in tables only if a threshold of 20% of enroled 
inpatients had a particular documented clinical result or 
classification. Logistic regression was also used to meas-
ure differences in hospitalisation rates by species of infec-
tion between age ranges. Results were represented as 
odds ratios with 95% confidence intervals (OR (95%)) as 
well as p values. Differences were considered to be sig-
nificant at p values ≤0.05.
Mixed P. falciparum and P. vivax infections were 
excluded from all statistical analyses due to the small 
sample size.
Results
Febrile and malaria‑positive cases at Goa Medical College 
and Hospital
A total of 74,571 febrile individuals presented to GMC 
between January 2012 and December 2015 and all were 
tested for malaria. Of those, 6287 (8.4%) were deter-
mined to be positive for malaria infection (Fig. 1). Over 
four years of passive surveillance, the number of malaria-
positive cases presenting to GMC steadily and signifi-
cantly increased, from 889 cases in 2012  to  2261 cases 
in 2015 (Fig. 2). While the traditional malaria season in 
Goa is June to December, P. falciparum and P. vivax cases 
were recorded throughout the year at GMC with the 
peak coinciding with the rainy season (Fig.  3). In 2015, 
the increase in malaria cases preceded the annual rains 
and case numbers remained high from April through 
December. The number of monthly cases observed at 
GMC during the height of the malaria season (Septem-
ber) was approximately five times greater than at the low-
est point during the middle of the dry season (February).  
Of the malaria-positive individuals presenting to GMC, 
the majority (86.8%) were diagnosed by the hospital with 
P. vivax mono-infection. Plasmodium falciparum infec-
tions accounted for 9.1%, and mixed infections for 4.1% 
of the total cases over four years (Fig. 3). Month-wise, the 
number of P. vivax infections was always greater than P. 
falciparum and mixed infections. The seasonality of P. 
vivax and P. falciparum infections was very similar, with 
case numbers of both increasing after the start of the 
rains. At the peak of the malaria transmission season as 
many as 10% of fever cases at GMC were malaria positive 
(Fig. 2).
Demographic characteristics of study participants
A total of 1116 of 6217 (18%) febrile individuals identi-
fied by GMC as malaria-positive via microscopy or RDT 
were enroled in the present study between April 2012 
and December 2015 (Fig.  1). Enrolment of this subset 
of patients was based on the logistical capabilities of 
the study team. All study participants had a mean age of 
27  years (median 24  years; IQR 20–32  years) and were 
predominantly male (91.0%). The male-to-female ratio of 
study participants was roughly similar to the gender dis-
tribution of febrile cases presenting to GMC (86.7% male 
and 13.3% female). The mean age of male study partici-
pants was 27 years (median 24 years, IQR 20–31), while 
the mean-age of non-pregnant female study participants 
was slightly older at 30  years (median 31  years, IQR 
19–40). A small minority of malaria-positive cases (51, 
4.6%) were children under the age of 16 years, of whom 
64.7% were male and 35.3% were female.
Study participants at GMC represented a very hetero-
geneous Indian population. Approximately one-tenth of 
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study participants (11.8%) were born in Goa and 88.2% 
were born in 26 other Indian states or outside of India 
(Fig.  4). The states with the greatest representation of 
study participants were the eastern states of Bihar with 
186 (16.7%) individuals, West Bengal with 179 (16.0%), 
Uttar Pradesh with 152 (13.6%), and Jharkhand with 111 
(9.9%). The majority of study participants (51.5%) self-
identified as construction workers while 4.7% self-identi-
fied as students, 3.0% as housewives, 1.7% as soldiers or 
police, 1.5% as office workers, 1.3% as factory workers, 
and 33.2% selected the option other.
Some 97.5% of study participants were confirmed to be 
Plasmodium positive by the MESA-ICEMR study team, 
with 77.0% of those cases being P. vivax, 21.0% P. falci-
parum and 2.0% mixed-infection positive. The majority 
of malaria-positive individuals (83.3%) were classified as 
having uncomplicated malaria and treated on an outpa-
tient basis based on the clinical judgement of the attend-
ing physician at GMC. While P. vivax infections were 
much more common than P. falciparum, a higher pro-
portion of hospitalised cases were P. falciparum posi-
tive (107/182, 58.8%) versus P. vivax positive (71/182, 
39.0%) and mixed-infection positive (4/182, 2.2%). All 
analyses presented below includes only patients with 
mono-infections.
Demographic and diagnostic characteristics of confirmed 
malaria patients
As expected, malaria patients infected with P. falciparum 
only were significantly more likely to have a higher para-
sitaemia than those infected with P. vivax mono-infection 
among both outpatient and inpatient groups (Table  1). 
The mean parasitaemia value among P. vivax cases was 
slightly higher for outpatients as compared to inpatients, 
though the difference was not significant.
To better understand the P. falciparum and P. vivax 
patient populations at GMC, univariate analyses using 
logistic regression with a primary outcome of malaria 
parasite species were performed. The demographic 
and basic diagnostic features associated with species of 
infection for all malaria-confirmed cases are shown in 
Table 2. Occupation as a construction worker was weakly 
correlated with P. vivax infection only (55%), albeit a 
significant proportion of P. falciparum cases (47%) self-
identified as construction workers. Higher parasitaemia, 
lower Hb, anaemia, severe anaemia and hospitalisation 
were all significantly associated with P. falciparum infec-
tion. Conversely, gender, age, geographic origin, tem-
perature, high fever, and severe fever did not significantly 
differ between P. falciparum and P. vivax cases.
Clinical characteristics of hospitalised confirmed malaria 
patients
Overall, 46.9% (107/228) of enroled P. falciparum 
patients were hospitalised compared with 8.5% (71/838) 
Fig. 1 Diagram of study enrolment at Goa Medical College and 
Hospital. Of the 74,517 febrile patients who presented to GMC and 
were tested for malaria, 6287 were positive by hospital diagnosis. Of 
the 6287 cases identified by the hospital between January 2012 and 
December 2015, 6217 were referred to the MESA‑ICEMR study team 
between April 2012 and December 2015. Of 6217, 1116 study partici‑
pants were enroled by the MESA‑ICEMR and 1088 were confirmed by 
the MESA‑ICEMR to be malaria positive. Excluding mixed infections, 
178 confirmed malaria cases were hospitalised by GMC
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of enroled P. vivax patients, demonstrating an expected 
strong skew toward inpatient care and treatment of P. fal-
ciparum versus P. vivax (logistic regression; p  <  0.001). 
Furthermore, there was a significant age-dependent 
increase in hospitalisations. All malaria-positive patients 
over 40  years of age infected with either P. falciparum 
or P. vivax were significantly more likely to be hospi-
talised than those between the ages of one and  20 and 
ages 21 and 40 with the same species of infection (logistic 
regression; P. vivax p < 0.001, P. falciparum p = 0.033).
Among inpatients with malaria-confirmed infections 
at GMC, those with P. falciparum were more severely ill 
according to the WHO severe malaria criteria (Table 3) 
[42, 43]. Approximately equal percentages of hospital-
ised P. falciparum (76.6%) and P. vivax (78.9%) cases 
presented with at least one severity indicator. Of these 
criteria, respiratory distress, jaundice and renal failure 
were the most common symptoms present among both 
P. falciparum (51, 40.7, 42%) and P. vivax (42.9, 32.1, 
19.7%). However, a significantly greater percentage of P. 
Fig. 2 Increasing febrile and malaria positive cases at Goa Medical College and Hospital over four years. In 2012, 889 malaria cases were identified 
out of 15,589 febrile cases. In 2013, 1477 malaria cases were identified out of 17,017 febrile cases. In 2014, 1660 malaria cases were identified out of 
19,454 febrile cases. In 2015, 2261 malaria cases were identified out of 22,511 febrile cases
Fig. 3 Monthly malaria positive cases by species with rainfall data over four years. In 2012, 721 P. vivax, 120 P. falciparum and 48 mixed malaria 
cases were diagnosed for a total of 889 annual malaria infections at GMC. In 2013, 1297 P. vivax, 116 P. falciparum and 64 mixed malaria cases were 
diagnosed for a total of 1477 annual malaria infections at GMC. In 2014, 1467 P. vivax, 111 P. falciparum and 82 mixed malaria cases were diagnosed 
for a total of 1660 annual malaria infections at GMC. In 2015, 1972 P. vivax, 223 P. falciparum and 66 mixed malaria cases were diagnosed for a total of 
2261 annual malaria infections at GMC
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falciparum inpatients presented with at least two (43.9%, 
p < 0.05) and at least three (29.9%, p < 0.01) severity fea-
tures compared with P. vivax inpatients, indicating that 
multi-organ involvement was much more common in 
hospitalised P. falciparum cases. There were six deaths 
among the 182 enroled malaria positive inpatients at 
GMC (6/182, 3.3%), all of which were P. falciparum cases 
(6/107, 5.6%).
In addition to increasing clinical severity (p  <  0.01), 
lower Glasgow coma score, higher blood urea nitrogen, 
higher serum creatinine, renal failure, per cent parasitae-
mia, severe anaemia, more days in the hospital and hos-
pitalisation for more than eight days were all significantly 
correlated (p < 0.05) with P. falciparum infection. Shock 
or circulatory collapse was the only feature that showed 
a greater frequency among hospitalised P. vivax cases 
as compared to P. falciparum, albeit numbers were low 
in both species of infections. Though hypoglyemia and 
acidosis were not routinely measured, one case of hypo-
glycaemia was observed in a P. falciparum patient (1/45, 
2.2%), while it was not seen among any of the tested P. 
vivax patients (0/13, 0%). Metabolic acidosis, when tested 
for, was observed more frequently in P. falciparum cases 
(12/33, 36.4%) as compared to P. vivax (2/19, 10.5%).
Discussion
The present four year study was undertaken to better 
understand malaria disease burden in a peri-urban set-
ting in India. The study points to a complex malaria situ-
ation in Goa with both P. vivax and P. falciparum cases 
year-round, a recent, substantial increase in the number 
of malaria-positive patients annually, a greater burden of 
disease from P. falciparum, and a highly diverse popula-
tion of Indian patients from 26 of 29 states.
Between 2012 and 2015, GMC saw 6277 malaria-
positive cases, with the number of P. falciparum and P. 
vivax patients increasing more than two-fold, from 889 
in 2012 to 2261 in 2015. In contrast, between 2012 and 
2015, the Indian National Vector Disease Control Pro-
gramme (NVBDCP) reported 4854 cases of malaria in 
the entire  state of Goa, 443 of which were caused by P. 
falciparum, and showed a more than two-fold decline in 
cases between 2012 (1714 cases) and 2015 (786 cases) 
[44]. Whether this discrepancy in malaria cases is due to 
an increase in the number of patients from other states, 
higher local transmission or some other cause remains 
to be determined. At the same time, these figures suggest 
that a large proportion of the total malaria cases in the 
state of Goa may be presenting to GMC and, thus, GMC 
may provide an approximation of malaria transmission 
and disease burden in the local community.
Despite the expected increase in number of malaria 
cases during and after the monsoon season, both P. vivax 
and P. falciparum patients were seen year-round at the 
GMC. While the year-round presence of P. vivax cases 
may be explained by the ability of P. vivax parasites to lie 
dormant as hypnozoites in liver stages with small num-
bers re-emerging during the dry season, this would not 
be the case for P. falciparum [8, 45]. Although it remains 
to be established, a more perennial transmission cycle 
of both P. vivax and P. falciparum may be aided by the 
recent discovery of a previously unsuspected vector in 
this region, Anopheles subpictus [46]. This vector has 
Fig. 4 Geographic heterogeneity of Goa Medical College malaria‑
positive study participants. Study participants at GMC represented a 
very heterogeneous Indian population and most study participants 
were born outside of Goa. The proportion of patients that were born 
in each state is shown
Table 1 Parasitaemia profiles by  unequal variances t test 
of Plasmodium falciparum and Plasmodium vivax patients
** p < 0.01; *** p < 0.001, # Welch correction, $ excludes mixed-infection cases
Number 
of cases$







P. falciparum P. vivax
Outpa‑
tients
121 767 1.30 ± 1.94% 0.56 ± 0.67% <0.001***
Inpatients 107 71 1.35 ± 3.31% 0.41 ± 0.65% 0.005**#
All 
patients
228 838 1.32 ± 2.67% 0.55 ± 0.67% <0.001***
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Table 2 Univariate logistic regression of demographic and diagnostic features by species of malaria infection
* p < 0.05; ** p < 0.01; *** p < 0.001, $ excludes mixed-infection cases
Feature P. falciparum$ P. vivax$ OR (95% CI) p value
Male, n/N (%) 210/228 (92.1) 768/838 (91.6) 1.1 (0.6–1.9) 0.806
Age, y, Mean ± SD 27.0 ± 11.2 27.4 ± 10.5 1.0 (1.0–1.0) 0.659
Construction workers, n/N (%) 107/228 (46.9) 461/838 (55.0) 0.7 (0.6–1.0) 0.046*
Born in Goa, n/N (%) 30/228 (13.2) 96/838 (11.5) 1.2 (0.8–1.9) 0.337
Born in SW India, n/N (%) 56/228 (24.6) 187/838 (22.3) 1.1 (0.8–1.6) 0.475
Born in E India, n/N (%) 134/228 (58.8) 545/838 (65.0) 0.8 (0.6–1.1) 0.103
% Parasitaemia, Mean ± SD 1.3 ± 2.7 0.6 ± 0.7 1.6 (1.4–1.9) <0.001***
Temperature, C, Mean ± SD 38.1 ± 1.6 38.2 ± 1.4 1.0 (0.9–1.0) 0.642
High fever (>38.1 °C), n/N (%) 104/228 (45.6) 380/838 (45.3) 1.0 (0.8–1.4) 0.769
Severe fever (>38.9 °C), n/N (%) 71/228 (31.1) 235/838 (28.0) 1.2 (0.9–1.7) 0.266
Haemoglobin, g/dL, Mean ± SD 10.9 ± 2.6 11.6 ± 2.1 0.9 (0.8–0.9) <0.001***
Anaemia, n/N (%) 42/219 (19.2) 90/837 (10.8) 2.0 (1.3–2.9) 0.001**
Severe anaemia, n/N (%) 15/219 (6.8) 14/837 (1.7) 4.3 (2.0–9.2) <0.001***
Hospitalisation, n/N (%) 107/228 (46.9) 71/838 (8.5) 9.1 (6.4–13.0) <0.001***
Table 3 Univariate logistic regression of clinical features by species of malaria infection among hospitalised patients
* p < 0.05; ** p < 0.01, $ excludes mixed-infection cases, SS # of WHO severe malaria criteria met at admission and during hospitalisation
Feature P. falciparum$ P. vivax$ OR (95% CI) p value
Glasgow coma score, Mean ± SD 13.8 ± 2.5 14.5 ± 1.5 0.8 (0.7–1.0) 0.040*
Coma, n/N (%) 10/107 (9.3) 2/71 (2.8) 3.7 (0.8– 17.9) 0.099
Blood urea nitrogen, mg  %, Mean ± SD 75.7 ± 82.0 38.3 ± 24.7 1.0 (1.0–1.0) 0.003**
Serum creatinine, mg/dL, Mean ± SD 2.2 ± 3.2 1.1 ± 0.5 1.4 (1.1–2.0) 0.027*
Renal failure, n/N (%) 42/100 (42.0) 12/61 (19.7) 3.0 (1.4–6.3) 0.004**
Respiration rate (breaths/m), Mean ± SD 23.2 ± 6.7 21.8 ± 8.7 1.0 (1.0–1.1) 0.395
Respiratory distress, n/N (%) 50/98 (51.0) 27/63 (42.9) 1.5 (0.8–2.8) 0.219
Total bilirubin, mg/dL, Mean ± SD 5.9 ± 8.6 3.5 ± 4.1 1.0 (1.0–1.0) 0.812
Jaundice, n/N (%) 35/86 (40.7) 18/56 (32.1) 1.5 (0.8–3.1) 0.225
Severe jaundice, n/N (%) 15/86 (17.4) 5/56 (8.9) 2.3 (0.8–6.7) 0.136
Systolic BP, mm Hg, Mean ± SD 99.0 ± 13.0 95.8 ± 13.4 1.0 (1.0–1.0) 0.107
Shock, n/N (%) 3/105 (2.9) 5/70 (7.1) 0.4 (0.9–1.8) 0.217
Pulmonary oedema, n/N (%) 9/106 (8.5) 5/72 (6.9) 1.5 (0.8–3.1) 0.225
Abnormal bleeding, n/N (%) 7/107 (6.5) 1/71 (1.4) 5.0 (0.6–43.4) 0.136
% Parasitaemia, Mean ± SD 1.4 ± 3.3 0.4 ± 0.7 1.5 (1.0–2.1) 0.024*
Temperature, C, Mean ± SD 37.7 ± 1.5 37.5 ± 1.4 1.0 (0.9–1.2) 0.481
High fever (>38.1 °C), n/N (%) 35/107 (32.7) 22/71 (31.0) 1.2 (0.6–2.3) 0.599
Severe fever (>38.9 °C), n/N (%) 19/107 (17.8) 13/71 (18.3) 1.0 (0.5–2.3) 0.918
Haemoglobin, g/dL, Mean ± SD 10.1 ± 2.7 10.6 ± 2.5 0.9 (0.8–1.0) 0.159
Anaemia, n/N (%) 33/107 (30.8) 16/71 (22.5) 1.6 (0.8–3.3) 0.157
Severe anaemia, n/N (%) 12/107 (11.2) 2/71 (2.8) 4.6 (1.0–21.9) 0.049*
Days in hospital, Mean ± SD 6.0 ± 5.5 4.6 ± 2.0 1.1 (1.0–1.2) 0.044*
Long hospital stay (>8 days), n/n (%) 18/107 (16.8) 3/71 (4.2) 4.7 (1.3–17.2) 0.016*
Severity, Mean ± SD 2.0 ± 2.02 1.2 ± 1.14 1.3 (1.1–1.67) 0.005**
Severe malaria (SS > 0), n/N (%) 82/107 (76.6) 56/71 (78.9) 1.1 (0.5–2.2) 0.818
Severe malaria (SS > 1), n/N (%) 47/107 (43.9) 19/71 (26.8) 2.2 (1.2–4.3) 0.014*
Severe malaria (SS > 2), n/N (%) 32/107 (29.9) 9/71 (12.7) 3.0 (1.3–7.0) 0.007**
Page 9 of 11Chery et al. Malar J  (2016) 15:569 
been shown to peak in numbers and transmission capac-
ity both after the monsoons when the traditional urban 
malaria vector Anopheles stephensi peaks, but also in the 
dry season when An. stephensi numbers are low.
Although P. vivax infections were much more com-
mon at GMC, P. falciparum infections were associated 
with greater severity. Although approximately equal 
proportions of hospitalised patients with P. falciparum 
and P. vivax had at least one WHO severe malaria fea-
ture, patients with two or more severity criteria were 
more common to P. falciparum cases. The six deaths that 
occurred among study participants were all P. falcipa-
rum patients. In recent years, there have been a number 
of studies pointing to the importance of severe P. vivax 
in Asia, with some suggesting that P. vivax may be as or 
nearly as virulent as P. falciparum [47–52]. In the pre-
sent study, though P. vivax caused some severe illness, 
multi-organ involvement was not typical. P. falciparum 
infections showed greater severity with substantial multi-
organ involvement.
There was a strikingly greater proportion of adult males 
(86.7%) presenting to GMC with P. falciparum and P. 
vivax malaria than adult females. The same gender bias 
was smaller for children enroled in the study, with 64.7% 
male children and 35.3% female children. Such findings 
are consistent with previous reports of age-dependent 
sex-bias in clinical malarial disease in hypo-endemic 
regions [53] and with the gender distribution of malaria-
positive patients at other MESA-ICEMR government ter-
tiary hospital sites in India (unpublished data). It is also 
important to consider the profile of individuals who com-
monly seek care at government hospitals, which may be a 
contributing factor.
Both P. falciparum and P. vivax patients over 40 years 
of age were significantly more likely to be hospitalised by 
GMC than those between the ages of one and 20  years 
and 21 and 40 years, which points to a possible increase 
in the susceptibility of older populations to severe 
malaria in lower transmission settings. Future analysis 
will explore age-related symptomology and outcomes as 
well as parasite and gametocyte carriage to better under-
stand if malaria virulence is increased in older popula-
tions in Goa. Other studies have shown that presenting 
syndromes in severe malaria depend on age and that 
age is an independent risk factor for a fatal outcome of 
malaria [16, 54, 55].
Construction sites in India are commonly suggested as 
potential transmission hot-spots, especially of severe P. 
falciparum, in low prevalence, relatively prosperous areas 
such as Goa [6, 56]. Though construction workers, who 
live and work at these sites and traditionally hail from the 
east and northeast states of India, accounted for roughly 
half of the malaria-positive study participants at GMC, 
they were nearly equally likely to be infected with P. vivax 
as P. falciparum. These findings may have implications 
for the conventional understanding of risk factors as well 
as the basis of targeted control measures at and around 
construction sites in the low transmission state of Goa. In 
the future, investigation to determine the possible effect 
of pre-existing P. falciparum and P. vivax immunity, 
compared across age, gender, origin and occupation, on 
transmission in Goa will be carried out.
There are a number of limitations to the present study. 
Due to logistical limitations and the high number of 
cases, only 18% of the hospital-identified malaria positive 
cases that presented to GMC over the study period were 
enroled. To date, there is not a complete, widely agreed-
upon definition of what clinical features constitute severe 
P. vivax disease, as compared to severe P. falciparum 
disease, globally or on the Indian subcontinent [52, 57]. 
As such, the WHO definition of severe malaria for P. fal-
ciparum infection was used for both species, as is gen-
erally the case, which may bias or weaken associations 
seen among P. vivax cases. The present study does not 
include data for splenomegaly, spleen rupture or throm-
bocytopaenia, which have been reported to be common 
among severe P. vivax cases and are not reflected in the 
WHO criteria [22, 24, 52]. Lactate, hypoglycaemia, and 
metabolic acidosis, all of which are important indica-
tors of severe malaria, were not routinely measured due 
to existing hospital practices. Malaria patients admitted 
to the GMC who required use of a ventilator, presumably 
due to respiratory distress [29, 47], which also has been 
commonly reported in severe P. vivax, were not included 
in the present study. This may impact the disease bur-
den being reported among P. vivax and/or P. falcipa-
rum cases. It was also not always possible to accurately 
determine whether a patient had co-infections and/or 
had been treated with anti-malarials prior to presenta-
tion at GMC, a tertiary care centre. Co-infections and/or 
prior treatment may have impacted the measurement of 
clinical severity and/or course of malaria infection [58]. 
Future studies will seek to present the dynamic course of 
infection among severe malaria patients at GMC.
Conclusion
The present study highlights the demographic, diag-
nostic and clinical profiles of P. falciparum and P. vivax 
patients at the only government tertiary care facility in 
a peri-urban setting in southwestern India. The num-
ber of malaria cases presenting to GMC increased more 
than two-fold from 2012 to 2015, which may be of inter-
est in the context of elimination efforts. The data from 
GMC show a greater burden of disease contributed by 
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P. falciparum than P. vivax and suggest a potential age-
dependent increase in susceptibility that will be further 
investigated.
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